Vimarsana
Biggest News Aggregation in the World

Page 4 - Briggs Morrison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Briggs Morrison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Briggs Morrison Today - Breaking & Trending Today

Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Earnings Results, Beats Expectations By $0.09 EPS - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Earnings Results, Beats Expectations By $0.09 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same period in the previous year, the firm earned ($0.62) earnings per share. Syndax Pharmaceuticals Stock Performance Shares of Syndax Pharmaceuticals […]

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $34.00 Price Target at Barclays - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $34.00 Price Target at Barclays

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target lifted by Barclays from $31.00 to $34.00 in a research report sent to investors on Wednesday, Marketbeat.com reports. They currently have an overweight rating on the stock. SNDX has been the subject of several other reports. StockNews.com raised shares of Syndax Pharmaceuticals to a sell […]

Syndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $36.00 - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $36.00

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price objective increased by stock analysts at B. Riley from $34.00 to $36.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm presently has a “buy” rating on the stock. B. Riley’s target price suggests a potential upside of 69.01% from the company’s […]

Syndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $42.00 - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $42.00

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its target price increased by Guggenheim from $40.00 to $42.00 in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 94.17% from the company’s […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Buy" from Analysts - Vimarsana News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Buy" from Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given an average rating of “Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last […]